In the recent case of Integra LifeSciences vs. Merck KGaA, the US Supreme Court has provided a broad exemption to patent infringement that could change the way that biotech deals are done: companies can now develop both generic and new drugs free from infringement. This feature discusses the negotiation of deals in light of the decision.